How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/epirubicin-or-doxorubicin-cyclophosphamide-paclitaxel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Epirubicin or doxorubicin, cyclophosphamide, paclitaxel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Epirubicin or doxorubicin, cyclophosphamide, paclitaxel (Epirubicin or doxorubicin, cyclophosphamide, paclitaxel) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy regimen (anthracycline + alkylating agent + taxane). Area: Oncology.

phase 3 Chemotherapy regimen (anthracycline + alkylating agent + taxane) DNA (topoisomerase II inhibition, alkylation); microtubules (paclitaxel) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Epirubicin or doxorubicin, cyclophosphamide, paclitaxel (Epirubicin or doxorubicin, cyclophosphamide, paclitaxel) — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. This is a chemotherapy regimen combining anthracyclines (epirubicin or doxorubicin) and cyclophosphamide followed by paclitaxel, which work by intercalating DNA and disrupting microtubule formation to kill rapidly dividing cancer cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Epirubicin or doxorubicin, cyclophosphamide, paclitaxel TARGET	Epirubicin or doxorubicin, cyclophosphamide, paclitaxel	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	phase 3	Chemotherapy regimen (anthracycline + alkylating agent + taxane)	DNA (topoisomerase II inhibition, alkylation); microtubules (paclitaxel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy regimen (anthracycline + alkylating agent + taxane) class)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Epirubicin or doxorubicin, cyclophosphamide, paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/epirubicin-or-doxorubicin-cyclophosphamide-paclitaxel. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab